Table 1.
Baseline characteristics of the study population*
| Characteristic | NSTEMI | STEMI | Unstable Angina |
|---|---|---|---|
| (n =1187) | (n = 253) | (n =1,222) | |
| Demographic characteristics | |||
| Age (years) | 69.6 (59.5,78.2) | 62.3 (53.3,71.9) | 65.5 (57.1,75.2) |
| Female | 419 (35.3) | 86 (34) | 402 (32.9) |
| Race | |||
| White | 847 (72.4) | 160 (64) | 969 (80.1) |
| Black | 296 (25.3) | 83 (33.2) | 211 (17.4) |
| Other | 27 (2.3) | 7 (2.8) | 30 (2.5) |
| Body mass index (kg/m2) | 27.2 (23.7,31.4) | 27.3 (24.7,31.1) | 28.1 (24.9,32.7) |
| Past medical history | |||
| Diabetes | 561 (47.3) | 84 (33.2) | 603 (49.3) |
| Peripheral vascular disease | 301 (25.4) | 31 (12.3) | 270 (22.1) |
| History of prior stroke | 241 (20.3) | 20 (7.9) | 258 (21.1) |
| History of prior CHF | 333 (28.1) | 27 (10.7) | 290 (23.7) |
| On lipid medication prior to hospitalization | 875 (73.7) | 214 (84.6) | 1101 (90.1) |
| Chronic kidney disease | 466 (39.3) | 40 (15.8) | 336 (27.5) |
| Chronic obstructive lung disease | 260 (21.9) | 36 (14.2) | 217 (17.8) |
| Admission characteristics | |||
| Pulse at presentation (bpm) | 97 (95,98) | 96 (95,98) | 97 (95,98) |
| Serum ALT (IU/L) | 25 (16,42.2) | 30 (20.5,50) | 20 (14,31) |
| HDL cholesterol (mg/dl) | 43 (35,53) | 44 (37,54) | 42 (35,52) |
| Ejection fraction (%) | 50 (35,55) | 45 (35,55) | 55 (45,55) |
| Maximum troponin T (mcg/L) | 0.4 (0.2,1.1) | 3.5 (1.8,7.5) | 0 (0,0) |
| Serum creatinine (mg/dl) | 1.1 (0.9,1.7) | 0.9 (0.8,1.2) | 1 (0.8,1.3) |
| Serum albumin (g/dl) | 3.5 (3,3.9) | 3.6 (3.3,3.9) | 3.9 (3.6,4.2) |
| Serum hematocrit (%) | 33.1 (30,37.4) | 36.2 (33,40.4) | 37.4 (33.1,40.8) |
| Events during hospitalization | |||
| Number of vessels with ≥50% stenoses | |||
| 0 | 76 (10.5) | 21 (8.3) | 155 (12.7) |
| 1 | 341 (47) | 232 (91.7) | 735 (60.3) |
| 2 | 73 (10.1) | 0 (0) | 128 (10.5) |
| 3 | 213 (29.4) | 0 (0) | 174 (14.3) |
| 4 | 22 (3) | 0 (0) | 26 (2.1) |
| Treatment | |||
| CABG | 197 (16.6) | 0 (0) | 92 (7.5) |
| Medical Management | 638 (53.7) | 0 (0) | 386 (31.6) |
| PCI-BMS | 149 (12.6) | 155 (61.3) | 216 (17.7) |
| PCI-DES | 175 (14.7) | 62 (24.5) | 456 (37.3) |
| PCI-Other | 28 (2.4) | 36 (14.2) | 72 (5.9) |
| Number of Vessels Treated | |||
| 0 | 641 (56.9) | 0 (0) | 386 (32.6) |
| 1 | 285 (25.3) | 230 (93.1) | 586 (49.5) |
| 2 | 84 (7.5) | 16 (6.5) | 144 (12.2) |
| 3 | 116 (10.3) | 1 (0.4) | 68 (5.7) |
| 4 | 0 (0) | 0 (0) | 1 (0.1) |
| Stroke during hospitalization | 33 (2.8) | 2 (0.8) | 23 (1.9) |
| New CHF in hospital | 137 (11.5) | 59 (23.3) | 60 (4.9) |
| Discharged to home | 967 (81.5) | 241 (95.3) | 1187 (97.1) |
| Medication utilization | |||
| Beta blocker in hospital | 1002 (84.4) | 213 (84.2) | 1091 (89.3) |
| Gp IIb/IIIa inhibitor for PCI | 255 (23.7) | 158 (86.8) | 135 (12.8) |
| Clopidogrel pre-procedure | 481 (44.2) | 248 (99.2) | 965 (81) |
| Clopidogrel at discharge | 753 (63.4) | 250 (98.8) | 1037 (84.9) |
*
There were 19 patients that had missing ACS type prior to imputation.
Values represent numbers (%) for dichotomous/categorical variables, and median (interquartile range) for continuous variables. ALT represents alanine aminotransferase; BMS, bare-metal stent; bpm, beats per minute; CABG, coronary artery bypass graft surgery; CHF, congestive heart failure; DES, drug-eluting stent; Gp, glycoprotein; HDL, high density lipoprotein; PCI, percutaneous coronary intervention.